Review

Circulating miRNAs: novel biomarkers of acute coronary syndrome?

Department of Internal Medicine, Division of Cardiovascular Medicine, The Ohio State University, 473 West 12th Avenue, OH 43210, USA.

Search for more papers by this author

Helina Selemon

Davis Heart & Lung Research Institute, The Ohio State University, 473 West 12th Avenue, OH 43210, USA

Search for more papers by this author

Shane M Elton

Midwestern University, Glendale, AZ, USA

Search for more papers by this author

Terry S Elton

* Author for correspondence

College of Pharmacy, Division of Pharmacology, The Ohio State University, 473 West 12th Avenue, OH 43210, USA.

Search for more papers by this author

Email the corresponding author at terry.elton@osumc.edu

Published Online:3 Apr 2013https://doi.org/10.2217/bmm.13.8

View article

Abstract

Acute coronary syndrome refers to any group of clinical symptoms compatible with acute myocardial infarction (AMI). AMI is a major cause of death and disability worldwide with the greatest risk of death within the first hours of AMI onset. Therefore, delays in ‘ruling in’ AMI may increase morbidity and mortality due to the time lag in initiating therapy. Likewise, since the majority of patients presenting with acute chest pain do not have AMI, the rapid ‘ruling out’ of AMI in those patients would increase emergency department triage efficiency, decrease medical costs, and reduce morbidity and mortality. Thus, the identification of novel biomarkers that improve current strategies and/or accurately identify subjects who are at risk of developing acute and chronic manifestations of cardiovascular disease are desperately needed. This article discusses the potential of peripheral blood microRNAs as clinical biomarkers for the diagnosis and prognosis of cardiovascular diseases such as AMI.

Keywords:

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

1 Rosamond W, Flegal K, Furie K et al. Heart disease and stroke statistics – 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation117,e25–e146 (2008).Crossref, Medline, Google Scholar
2 Lloyd-Jones D, Adams RJ, Brown TM et al. Executive summary: heart disease and stroke statistics – 2010 update: a report from the American Heart Association. Circulation121,948–954 (2010).Crossref, Medline, Google Scholar
3 Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet353,89–92 (1999).Crossref, Medline, CAS, Google Scholar
4 Gibler WB, Cannon CP, Blomkalns AL et al. Practical implementation of the guidelines for unstable angina/non-ST-segment elevation myocardial infarction in the emergency department. Ann. Emerg. Med.46,185–197 (2005).Crossref, Medline, Google Scholar
5 Pollack CV Jr, Diercks DB, Roe MT, Peterson ED. 2004 American College of Cardiology/American Heart Association guidelines for the management of patients with ST-elevation myocardial infarction: implications for emergency department practice. Ann. Emerg. Med.45,363–376 (2005).Crossref, Medline, Google Scholar
6 Antman EM, Anbe DT, Armstrong PW et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction – executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation110,588–636 (2004).Crossref, Medline, Google Scholar
7 Pollack CV Jr, Antman EM, Hollander JE. 2007 focused update to the ACC/AHA guidelines for the management of patients with ST-segment elevation myocardial infarction: implications for emergency department practice. Ann. Emerg. Med.52,344–355 (2008).Crossref, Medline, Google Scholar
8 Yeghiazarians Y, Braunstein JB, Askari A, Stone PH. Unstable angina pectoris. N. Engl. J. Med.342,101–114 (2000).Crossref, Medline, CAS, Google Scholar
9 Braunwald E. Unstable angina: an etiologic approach to management. Circulation98,2219–2222 (1998).Crossref, Medline, CAS, Google Scholar
10 Jneid H, Anderson JL, Wright RS et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol.60,645–681 (2012).Crossref, Medline, Google Scholar
11 Harrington RA, Becker RC, Cannon CP et al. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest133,670S–707S (2008).Crossref, Medline, CAS, Google Scholar
12 Antman EM, Cohen M, Bernink PJ et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA284,835–842 (2000).Crossref, Medline, CAS, Google Scholar
13 O’Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA Guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation127,529–555 (2013).Crossref, Medline, Google Scholar
14 Sabatine MS, Morrow DA, de Lemos JA, Jarolim P, Braunwald E. Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 35. Eur. Heart. J.30,162–169 (2009).Crossref, Medline, CAS, Google Scholar
15 Kurz K, Giannitsis E, Zehelein J, Katus HA. Highly sensitive cardiac troponin T values remain constant after brief exercise – or pharmacologic-induced reversible myocardial ischemia. Clin. Chem.54,1234–1238 (2008).Crossref, Medline, CAS, Google Scholar
16 Shave R, George KP, Atkinson G et al. Exercise-induced cardiac troponin T release: a meta-analysis. Med. Sci. Sports Exerc.39,2099–2106 (2007).Crossref, Medline, CAS, Google Scholar
17 Gupta S, de Lemos JA. Use and misuse of cardiac troponins in clinical practice. Prog. Cardiovasc. Dis.50,151–165 (2007).Crossref, Medline, CAS, Google Scholar
18 Müller-Bardorff M, Weidtmann B, Giannitsis E, Kurowski V, Katus HA. Release kinetics of cardiac troponin T in survivors of confirmed severe pulmonary embolism. Clin. Chem.48,673–675 (2002).Crossref, Medline, CAS, Google Scholar
19 Puleo PR, Meyer D, Wathen C et al. Use of a rapid assay of subforms of creatine kinase-MB to diagnose or rule out acute myocardial infarction. N. Engl. J. Med.331,561–566 (1994).Crossref, Medline, CAS, Google Scholar
20 Saenger AK, Jaffe AS. Requiem for a heavyweight: the demise of creatine kinase-MB. Circulation118,2200–2206 (2008).Crossref, Medline, Google Scholar
21 Goodman SG, Steg PG, Eagle KA et al. The diagnostic and prognostic impact of the redefinition of acute myocardial infarction: lessons from the Global Registry of Acute Coronary Events (GRACE). Am. Heart J.151,654–660 (2006).Crossref, Medline, Google Scholar
22 Hochholzer W, Buettner HJ, Trenk D et al. New definition of myocardial infarction: impact on long-term mortality. Am. J. Med.121,399–405 (2008).Crossref, Medline, Google Scholar
23 Hochholzer W, Reichlin T, Stelzig C et al. Impact of soluble fms-like tyrosine kinase-1 and placental growth factor serum levels for risk stratification and early diagnosis in patients with suspected acute myocardial infarction. Eur. Heart J.32,326–335 (2011).Crossref, Medline, CAS, Google Scholar
24 Macrae AR, Kavsak PA, Lustig V et al. Assessing the requirement for the 6-hour interval between specimens in the American Heart Association Classification of Myocardial Infarction in Epidemiology and Clinical Research Studies. Clin. Chem.52,812–818 (2006).Crossref, Medline, CAS, Google Scholar
25 Apple FS, Murakami MM. Cardiac troponin and creatine kinase MB monitoring during in-hospital myocardial reinfarction. Clin. Chem.51,460–463 (2005).Crossref, Medline, CAS, Google Scholar
26 Vasile VC, Babuin L, Giannitsis E, Katus HA, Jaffe AS. Relationship of MRI-determined infarct size and cTnI measurements in patients with ST-elevation myocardial infarction. Clin. Chem.54,617–619 (2008).Crossref, Medline, CAS, Google Scholar
27 Olatidoye AG, Wu AH, Feng YJ, Waters D. Prognostic role of troponin T versus troponin I in unstable angina pectoris for cardiac events with meta-analysis comparing published studies. Am. J. Cardiol.81,1405–1410 (1998).Crossref, Medline, CAS, Google Scholar
28 Heeschen C, Hamm CW, Goldmann B, Deu A, Langenbrink L, White HD. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management. Lancet354,1757–1762 (1999).Crossref, Medline, CAS, Google Scholar
29 Heidenreich PA, Alloggiamento T, Melsop K, McDonald KM, Go AS, Hlatky A. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis. J. Am. Coll. Cardiol.38,478–485 (2001).Crossref, Medline, CAS, Google Scholar
30 Panteghini M, Pagani F, Yeo KT et al. Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin. Chem.50,327–332 (2004).Crossref, Medline, CAS, Google Scholar
31 Wu AH, Feng YJ, Moore R et al. Characterization of cardiac troponin subunit release into serum after acute myocardial infarction and comparison of assays for troponin T and I. American Association for Clinical Chemistry Subcommittee on cTnI Standardization. Clin. Chem.44,1198–1208 (1998).Crossref, Medline, CAS, Google Scholar
32 Thygesen K, Alpert JS, Jaffe AS et al. Third universal definition of myocardial infarction. J. Am. Coll. Cardiol.60,1581–1598 (2012).Crossref, Medline, Google Scholar
33 Kavsak PA, Newman AM, Lustig V et al. Long-term health outcomes associated with detectable troponin I concentrations. Clin. Chem.53,220–227 (2007).Crossref, Medline, CAS, Google Scholar
34 Waxman DA, Hecht S, Schappert J, Husk G. A model for troponin I as a quantitative predictor of in-hospital mortality. J. Am. Coll. Cardiol.48,1755–1762 (2006).Crossref, Medline, CAS, Google Scholar
35 Schulz O, Kirpal K, Stein J et al. Importance of low concentrations of cardiac troponins. Clin. Chem.52,1614–1615 (2006).Crossref, Medline, CAS, Google Scholar
36 Daniels LB, Laughlin GA, Clopton P, Maisel AS, Barrett-Connor E. Minimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults: results from the Rancho Bernardo Study. J. Am. Coll. Cardiol.52,450–459 (2008).Crossref, Medline, CAS, Google Scholar
37 Kavsak PA, Wang X, Ko DT, MacRae AR, Jaffe AS. Short- and long-term risk stratification using a next-generation, high-sensitivity research cardiac troponin I (hs-cTnI) assay in an emergency department chest pain population. Clin. Chem.55,1809–1815 (2009).Crossref, Medline, CAS, Google Scholar
38 deFilippi CR, de Lemos JA, Christenson RH et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA304,2494–2502 (2010).Crossref, Medline, CAS, Google Scholar
39 Diamond GA, Kaul S. How would the Reverend Bayes interpret high-sensitivity troponin? Circulation121,1172–1175 (2010).Crossref, Medline, Google Scholar
40 Franz WM, Remppis A, Kandolf R, Kübler W, Katus HA. Serum troponin T: diagnostic marker for acute myocarditis. Clin. Chem.42,340–341 (1996).Crossref, Medline, CAS, Google Scholar
41 Babuin L, Vasile VC, Rio Perez JA et al. Elevated cardiac troponin is an independent risk factor for short- and long-term mortality in medical intensive care unit patients. Crit. Care Med.36,759–765 (2008).Crossref, Medline, CAS, Google Scholar
42 Allan JJ, Feld RD, Russell AA et al. Cardiac troponin I levels are normal or minimally elevated after transthoracic cardioversion. J. Am. Coll. Cardiol.30,1052–1056 (1997).Crossref, Medline, CAS, Google Scholar
43 Ricchiuti V, Apple FS. RNA expression of cardiac troponin T isoforms in diseased human skeletal muscle. Clin. Chem.45,2129–2135 (1999).Crossref, Medline, CAS, Google Scholar
44 Jaffe AS, Vasile VC, Milone M, Saenger AK, Olson KN, Apple FS. Diseased skeletal muscle: a noncardiac source of increased circulating concentrations of cardiac troponin T. J. Am. Coll. Cardiol.58,1819–1824 (2011).Crossref, Medline, Google Scholar
45 Emilian C, Goretti E, Prospert F et al. MicroRNAs in patients on chronic hemodialysis (MINOS study). Clin. J. Am. Soc. Nephrol.7,619–623 (2012).Crossref, Medline, Google Scholar
46 Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell75,843–854 (1993).Crossref, Medline, CAS, Google Scholar
47 Bushati N, Cohen SM. microRNA functions. Annu. Rev. Cell Dev. Biol.23,175–205 (2007).Crossref, Medline, CAS, Google Scholar
48 Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell136,215–233 (2009).Crossref, Medline, CAS, Google Scholar
49 Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res.1,92–105 (2009).Google Scholar
50 Landgraf P, Rusu M, Sheridan R et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell129,1401–1414 (2007).Crossref, Medline, CAS, Google Scholar
51 Liu N, Olson EN. MicroRNA regulatory networks in cardiovascular development. Dev. Cell18,510–525 (2010).Crossref, Medline, CAS, Google Scholar
52 Leung AK, Sharp PA. MicroRNA functions in stress responses. Mol. Cell40,205–215 (2010).Crossref, Medline, CAS, Google Scholar
53 Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease. Cell148,1172–1187 (2012).Crossref, Medline, CAS, Google Scholar
54 Rüegger S, Großhans H. MicroRNA turnover: when, how, and why. Trends Biochem. Sci.37,436–446 (2012).Crossref, Medline, CAS, Google Scholar
55 Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat. Rev. Mol. Cell Biol.10,126–139 (2009).Crossref, Medline, CAS, Google Scholar
56 Fabian MR, Sonenberg N. The mechanics of miRNA mediated gene silencing: a look under the hood of miRISC. Nat. Struct. Mol. Biol.19,586–593 (2012).Crossref, Medline, CAS, Google Scholar
57 Shin C. Cleavage of the star strand facilitates assembly of some microRNAs into Ago2-containing silencing complexes in mammals. Mol. Cells26,308–313 (2008).Medline, CAS, Google Scholar
58 Okamura K, Phillips MD, Tyler DM, Duan H, Chou YT, Lai EC. The regulatory activity of microRNA* species has substantial influence on microRNA and 3’ UTR evolution. Nat. Struct. Mol. Biol.15,354–363 (2008).Crossref, Medline, CAS, Google Scholar
59 Packer AN, Xing Y, Harper SQ, Jones L, Davidson BL. The bifunctional microRNA, miR-9/miR-9*, regulates REST and CoREST and is downregulated in Huntington’s disease. J. Neurosci.28,14341–14346 (2008).Crossref, Medline, CAS, Google Scholar
60 Yang JS, Phillips MD, Betel D et al. Widespread regulatory activity of vertebrate microRNA* species. RNA17,312–326 (2011).Crossref, Medline, CAS, Google Scholar
61 Griffiths-Jones S. The microRNA registry. Nucleic Acids Res.32,D109–D111 (2004).Crossref, Medline, CAS, Google Scholar
62 Brennecke J, Stark A, Russell RB, Cohen SM. Principles of microRNA-target recognition. PLoS Biol.3,e85 (2005).Crossref, Medline, Google Scholar
63 Guo H, Ingolia NT, Weissman J S, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature466,835–840 (2010).Crossref, Medline, CAS, Google Scholar
64 Brown BD, Gentner B, Cantore A et al. Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat. Biotechnol.25,1457–1467 (2007).Crossref, Medline, CAS, Google Scholar
65 Mullokandov G, Baccarini A, Ruzo A et al. High-throughput assessment of microRNA activity and function using microRNA sensor and decoy libraries. Nat. Methods9,840–846 (2012).▪ Over 60% of detected miRNAs had no discernible activity.Crossref, Medline, CAS, Google Scholar
66 Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell146,353–358 (2011).Crossref, Medline, CAS, Google Scholar
67 Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. USA105,10513–10518 (2008).Crossref, Medline, CAS, Google Scholar
68 Chen X, Ba Y, Ma L et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res.18,997–1006 (2008).Crossref, Medline, CAS, Google Scholar
69 Lawrie CH, Gal S, Dunlop HM et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br. J. Haematol.141,672–675 (2008).Crossref, Medline, Google Scholar
70 Simons M, Raposo G. Exosomes – vesicular carriers for intercellular communication. Curr. Opin. Cell Biol.21,575–581 (2009).Crossref, Medline, CAS, Google Scholar
71 Bang C, Thum T. Exosomes: new players in cell–cell communication. Int. J. Biochem. Cell Biol.44,2060–2064 (2012).Crossref, Medline, CAS, Google Scholar
72 Mause SF, Weber C. Microparticles: Protagonists of a novel communication network for intercellular information exchange. Circ. Res.107,1047–1057 (2010).Crossref, Medline, CAS, Google Scholar
73 Zernecke A, Bidzhekov K, Noels H et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci. Signal.2,ra81 (2009).Crossref, Medline, Google Scholar
74 Wang K, Zhang S, Weber J, Baxter D, Galas DJ. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res.38,7248–7259 (2010).Crossref, Medline, CAS, Google Scholar
75 Arroyo JD, Chevillet JR, Kroh EM et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl Acad. Sci. USA108,5003–5008 (2011).▪▪ Extracellular Ago2–miRNA complexes are stable in the plasma, raising the possibility that cells release a functional miRNA-induced silencing complex into the circulation.Crossref, Medline, CAS, Google Scholar
76 Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res.39,7223–7233 (2011).Crossref, Medline, CAS, Google Scholar
77 Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol.13,423–433 (2011).▪▪ High-density lipoprotein participates in a mechanism of intercellular communication involving the transport and delivery of miRNAs.Crossref, Medline, CAS, Google Scholar
78 Etheridge A, Lee I, Hood L, Galas D, Wang K. Extracellular microRNA: a new source of biomarkers. Mutat. Res.717,85–90 (2011).Crossref, Medline, CAS, Google Scholar
79 Small EM, Olson EN. Pervasive roles of microRNAs in cardiovascular biology. Nature469,336–342 (2011).Crossref, Medline, CAS, Google Scholar
80 van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science316,575–579 (2007).Crossref, Medline, CAS, Google Scholar
81 Condorelli G, Latronico MV, Dorn GW II. MicroRNAs in heart disease: putative novel therapeutic targets? Eur. Heart J.31,649–658 (2010).Crossref, Medline, CAS, Google Scholar
82 Olivieri F, Antonicelli R, Lorenzi M et al. Diagnostic potential of circulating miR-499-5p in elderly patients with acute non ST-elevation myocardial infarction. Int. J. Cardiol. doi:10.1016/j.ijcard.2012.01.075 (2012) (Epub ahead of print).▪ Circulating miR-499-5p is a sensitive biomarker of acute non-ST elevation myocardial infarction in the elderly, exhibiting a diagnostic accuracy superior to that of cardiac troponin T in patients with modest elevation at presentation.Google Scholar
83 Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell145,341–355 (2011).Crossref, Medline, CAS, Google Scholar
84 Guo M, Mao X, Ji Q et al. miR-146a in PBMCs modulates Th1 function in patients with acute coronary syndrome. Immunol. Cell Biol.88,555–564 (2010).Crossref, Medline, CAS, Google Scholar
85 Yao R, Ma Y, Du Y et al. The altered expression of inflammation-related microRNAs with microRNA-155 expression correlates with Th17 differentiation in patients with acute coronary syndrome. Cell Mol. Immunol.8,486–495 (2011).Crossref, Medline, CAS, Google Scholar
86 Zampetaki A, Willeit P, Tilling L et al. Prospective study on circulating microRNAs and risk of myocardial infarction. J. Am. Coll. Cardiol.60,290–299 (2012).▪▪ In subjects with subsequent myocardial infarction, differential coexpression patterns of circulating miRNAs occur around endothelium-enriched miR-126, with platelets being a major contributor to this miRNA signature.Crossref, Medline, CAS, Google Scholar
87 Ji X, Takahashi R, Hiura Y, Hirokawa G, Fukushima Y, Iwai N. Plasma miR-208 as a biomarker of myocardial injury. Clin. Chem.55,1944–1949 (2009).Crossref, Medline, CAS, Google Scholar
88 Wang GK, Zhu JQ, Zhang JT et al. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur. Heart J.31,659–666 (2010).▪ Elevated cardiac-specific miR-208a in plasma may be a novel biomarker for the early detection of myocardial injury in humans.Crossref, Medline, Google Scholar
89 Cheng Y, Tan N, Yang J et al. A translational study of circulating cell-free microRNA-1 in acute myocardial infarction. Clin. Sci. (Lond.)119,87–95 (2010).Crossref, Medline, CAS, Google Scholar
90 D’Alessandra Y, Devanna P, Limana F et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur. Heart J.31,2765–2773 (2010).Crossref, Medline, Google Scholar
91 Gidlof O, Andersson P, van der Pals J, Gotberg M, Erlinge D. Cardiospecific microRNA plasma levels correlate with troponin and cardiac function in patients with ST elevation myocardial infarction, are selectively dependent on renal elimination, and can be detected in urine samples. Cardiology118,217–226 (2011).Crossref, Medline, Google Scholar
92 Adachi T, Nakanishi M, Otsuka Y et al. Plasma microRNA 499 as a biomarker of acute myocardial infarction. Clin. Chem.56,1183–1185 (2010).Crossref, Medline, CAS, Google Scholar
93 Corsten MF, Dennert R, Jochems S et al. Circulating microRNA-208b and microRNA-499 reflect myocardial damage in cardiovascular disease. Circ. Cardiovasc. Genet.3,499–506 (2010).Crossref, Medline, Google Scholar
94 Kuwabara Y, Ono K, Horie T et al. Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circ. Cardiovasc. Genet.4,446–454 (2011).Crossref, Medline, CAS, Google Scholar
95 Fichtlscherer S, De Rosa S, Fox H et al. Circulating microRNAs in patients with coronary artery disease. Circ. Res.107,677–684 (2010).Crossref, Medline, CAS, Google Scholar
96 De Rosa S, Fichtlscherer S, Lehmann R, Assmus B, Dimmeler S, Zeiher AM. Transcoronary concentration gradients of circulating microRNAs. Circulation124,1936–1944 (2011).Crossref, Medline, CAS, Google Scholar
97 Devaux Y, Vausort M, Goretti E et al. Use of circulating microRNAs to diagnose acute myocardial infarction. Clin. Chem.58,559–567 (2012).▪▪ Largest patient cohort, to date, demonstrating that miR-499 and high-sensitivity cardiac troponin T provided comparable diagnostic markers of acute myocardial ischemia.Crossref, Medline, CAS, Google Scholar
98 Ai J, Zhang R, Li Y et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem. Biophys. Res. Commun.391,73–77 (2010).Crossref, Medline, CAS, Google Scholar
99 Widera C, Gupta SK, Lorenzen JM et al. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J. Mol. Cell. Cardiol.51,872–875 (2011).Crossref, Medline, CAS, Google Scholar
100 Goch A, Misiewicz P, Rysz J, Banach M. The clinical manifestation of myocardial infarction in elderly patients. Clin. Cardiol.32,E46–E51 (2009).Crossref, Medline, Google Scholar
101 Meder B, Keller A, Vogel B et al. MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction. Basic Res. Cardiol.106,13–23 (2011).▪ Single miRNAs and especially miRNA signatures derived from peripheral blood can be valuable novel biomarkers for acute myocardial ischemia.Crossref, Medline, CAS, Google Scholar
102 Wang R, Li N, Zhang Y, Ran Y, Pu J. Circulating MicroRNAs are promising novel biomarkers of acute myocardial infarction. Intern. Med.50,1789–1795 (2011).Crossref, Medline, CAS, Google Scholar
103 Lu Y, Zhang Y, Wang N et al. MicroRNA-328 contributes to adverse electrical remodeling in atrial fibrillation. Circulation122,2378–2387 (2010).Crossref, Medline, CAS, Google Scholar
104 Methe H, Brunner S, Wiegand D, Nabauer M, Koglin J, Edelman ER. Enhanced T helper-1 lymphocyte activation patterns in acute coronary syndromes. J. Am. Coll. Cardiol.45,1939–1945 (2005).Crossref, Medline, CAS, Google Scholar
105 Nakasa T, Miyaki S, Okubo A et al. Expression of microRNA-146 in rheumatoid arthritis synovial tissue. Arthritis Rheum.58,1284–1292 (2008).Crossref, Medline, CAS, Google Scholar
106 Kiechl S, Lorenz E, Reindl M et al. Toll-like receptor 4 polymorphisms and atherogenesis. N. Engl. J. Med.347,185–192 (2002).Crossref, Medline, CAS, Google Scholar
107 Matsumoto S, Sakata Y, Nakatani D et al. A subset of circulating microRNAs are predictive for cardiac death after discharge for acute myocardial infarction. Biochem. Biophys. Res. Commun.427,280–284 (2012).Crossref, Medline, CAS, Google Scholar
108 Lee LW, Zhang S, Etheridge A et al. Complexity of the microRNA repertoire revealed by next-generation sequencing. RNA16,2170–2180 (2010).Crossref, Medline, CAS, Google Scholar
109 Chen X, Ba Y, Ma L et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res.18,997–1006 (2008).Crossref, Medline, CAS, Google Scholar
110 Hu Z, Chen X, Zhao Y et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J. Clin. Oncol.28,1721–1726 (2010).Crossref, Medline, Google Scholar
111 Diehl P, Fricke A, Sander L et al. Microparticles: major transport vehicles for distinct microRNAs in circulation. Cardiovasc. Res.93,633–644 (2012).Crossref, Medline, CAS, Google Scholar
112 Sondermeijer BM, Bakker A, Halliani A et al. Platelets in patients with premature coronary artery disease exhibit upregulation of miRNA340* and miRNA624*. PLoS One6,e25946 (2011).Crossref, Medline, CAS, Google Scholar
113 Minami Y, Satoh M, Maesawa C et al. Effect of atorvastatin on microRNA 221/222 expression in endothelial progenitor cells obtained from patients with coronary artery disease. Eur. J. Clin. Invest.39,359–367 (2009).Crossref, Medline, CAS, Google Scholar
114 Pritchard CC, Kroh E, Wood B et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev. Res. (Phila)5,492–497 (2012).Crossref, Medline, CAS, Google Scholar
115 Zampetaki A, Kiechl S, Drozdov I et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ. Res.107,810–817 (2010).Crossref, Medline, CAS, Google Scholar
116 Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease: the present and the future. J. Am. Coll. Cardiol.48,1–11 (2006).Crossref, Medline, CAS, Google Scholar
201 miRBase. www.mirbase.org/index.shtmlGoogle Scholar

Vol. 7, No. 2

Metrics

Downloaded 352 times

History

Published online 3 April 2013

Published in print April 2013

Information

Keywords

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download